CPI-0610 clinical trials
Also written Pelabresib, CPI-0610 and DAK539.
How each study uses CPI-0610 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CPI-0610 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Novartis Pharmaceuticals (7) · Constellation Pharmaceuticals (4) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Repaglinide (1) · Midazolam (1) · Drospirenone (1) · Ethinyl Estradiol (1) · Phenytoin (1) · Itraconazole (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CPI-0610.
- Nov 2026A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy ParticipantsPhase 1 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses CPI-0610 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)RecruitingPhase 3Novartis PharmaceuticalsNCT07357727Written as Pelabresib
- An Extension Study for Patients Previously Enrolled in Studies With PelabresibRecruitingPhase 3Novartis PharmaceuticalsNCT06401356Written as Pelabresib
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRecruitingPhase 1Novartis PharmaceuticalsNCT07340190Written as pelabresib
- A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy ParticipantsRecruitingPhase 1Novartis PharmaceuticalsNCT07783503Written as Pelabresib
- Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic ImpairmentRecruitingPhase 1Novartis PharmaceuticalsNCT07422610Written as pelabresib
- Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive, not recruitingPhase 1Novartis PharmaceuticalsNCT07340138Written as Pelabresib
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT04603495Written as Pelabresib
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedPhase 1/2Constellation PharmaceuticalsNCT02158858Written as Pelabresib
- Study Evaluating Food Effect and QTc in Patients With Advanced MalignanciesCompletedPhase 1Constellation PharmaceuticalsNCT05391022Written as Pelabresib
- A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive LymphomaCompletedPhase 1Constellation PharmaceuticalsNCT01949883Written as CPI-0610
- A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple MyelomaCompletedPhase 1Constellation PharmaceuticalsNCT02157636Written as CPI-0610
- Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath TumorsWithdrawnPhase 2University of Texas Southwestern Medical CenterNCT02986919Written as CPI-0610